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ABSTRACT
The induced pluripotent stem cells (iPSCs), derived by
ectopic expression of reprogramming factors in somatic
cells, can potentially provide unlimited autologous cells
for regenerative medicine. In theory, the autologous
cells derived from patient iPSCs should be immune
tolerant by the host without any immune rejections.
However, our recent studies have found that even syn-
geneic iPSC-derived cells can be immunogenic in syn-
geneic hosts by using a teratoma transplantation model
(Nature 474:212–215, 2011). Recently two research
groups differentiated the iPSCs into different germ lay-
ers or cells, transplanted those cells to the syngeneic
hosts, and evaluated the immunogenicity of those cells.
Both of the two studies support our conclusions that
some certain but not all tissues derived from iPSCs can
be immunogenic, although they claimed either “negli-
gible” or “lack of” immunogenicity in iPSC derivatives
(Nature 494:100–104, 2013; Cell Stem Cell 12:407–412,
2013). To test the immunogenicity of clinically valuable
cells differentiated from human iPSCs are emergently
required for translation of iPSC technology to clinics.
The embryonic stem cells (ESCs), characterized by the
capability to both self-renew and differentiate into each cell
type, hold great promise for regenerative medicine. How-
ever, the ethical concern and immune rejection are the two
major hurdles for clinical development of ESCs. The induced
pluripotent stem cell (iPSC), developed by Yamanaka group
in 2006 through ectopic expression of four reprogramming
factors in terminally differentiated somatic cells (Takahashi
and Yamanaka, 2006), is believed to be able to get cross
those barriers. This breakthrough discovery has greatly
reshaped the scientiﬁc and political landscapes of stem cell
biology. It provides an unprecedented opportunity to model
human disease, re-understand the basic biology such as
development and differentiation, identify new therapeutic
targets and test new therapies etc. Most importantly, the
iPSC can potentially provide autologous cell resources in
regenerative medicine without concerning the immune
rejections led by major histocompatibility complex restriction.
It raised the hope that patient-speciﬁc iPSCs could become
a renewable source of autologous cells for human therapy.
Whereas it has been widely predicted that the autologous
cells derived from patient-speciﬁc iPSCs are immune toler-
ant in that patient, the immunogenicity of cells derived from
iPSC has not been widely examined since the discovery of
the iPSCs.
By using a teratoma formation model, we unexpectedly
found that some but not all cells derived from mouse iPSC
can be immunogenic (Zhao et al., 2011), and the immune
rejection response was T cell dependent, supported by the
immune rejection was totally blocked in Rag knock-out
recipients. Furthermore, in our system we identiﬁed two
genes (Hormad1 and Zg16), which were abnormally
expressed in iPSC-teratoma but not in ES-teratoma, directly
contribute to the immunogenicity of iPSC derivatives, sup-
porting by the existence of primed T cells in the mice har-
boring the iPSC derived teratomas.
The question whether iPSC derivatives are immnogeneic
or not is straight forward; however, the answer to this
question is very complicated due to the developmental ran-
domness of iPSC and the nondeterminacy of the abnormal
expression of the minor antigens. The ﬁrst hurdle to resolve
this question is the hardness to differentiate iPSC into each
tissue of our body and test their immunogenicity one by one.
The iPSC can produce any kind of tissues in a whole body
theoretically, however the directed differentiation of iPSC is
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still hindered by the low efﬁciency and it is still impossible to
differentiate iPSC into each tissue we need at current stage.
The original idea to use teratoma as a model system to test
iPSC immunogenicity is that teratoma contains many kinds
of tissues differentiated from pluripotent stem cells and it has
been successfully used to test the immunogenicity of ES
derivatives (Koch et al., 2008). A teratoma is an encapsu-
lated benign tumor harboring many kinds of tissue or organ
components resembling normal derivatives of all three germ
layers (Tapper and Lack, 1983; Chi et al., 1984), which
provide a possibility to probe the immunogenicity of iPSC
derived tissues as much as possible in a time. Recently, Dr.
Abe’s group studied the immunogenicity of different tissues
derived from iPSC including skin cells, bone marrow cells
and cardiomyocytes and found that iPSC derived cardio-
myocytes in vitro but not skin and bone marrow cells are
highly immunogenic (For further details, please refer to Sup
Fig. 13 in Araki et al., 2013). It is possible that the cardio-
myocytes, but not skin and bone marrow cells, harbor the
abnormal expressed minor antigens which contribute to the
immunogenicity. Another concern is that using the bone
marrow transplantation to study the intrinsic immunogenicity
of iPCS derivatives is inappropriate, because the hemato-
poietic stem cells inside the bone marrow can itself develop
into different linear of immune cells including regulatory T
cells leading to immune tolerance of the graft. In clinic, the
pre-transplantation of donor hematopoietic stem cell into the
recipients before transplanting the designed organs is rou-
tinely used to induce tolerance of allografting. Meanwhile, by
differentiation of iPSC into endothelial cells, hepatocytes and
neuronal cells, Boyd group studied the immunogenicity of
in vitro differentiated iPSC derivatives (Guha et al., 2013).
Although compared to the counterparts of allografts, the
immune rejection response led by syngeneic iPSC descen-
dents was mild, however, the endothelial cells derived from
iPSCs showed higher apoptosis rate than syngeneic ES
derivatives when cocultured with T cell isolated from endo-
thelial cell experienced syngeneic mice, indicating the iPSC
derived endothelial cells can induce immune rejection
response (For further details, please refer to Fig. 2E in Guha
et al., 2013).
The immunogenicity of iPSC derivatives is very compli-
cated (Fig. 1). It is widely accepted that reprogramming itself
can induce both genetic and epigenetic defects in iPSCs
(Doi et al., 2009; Kim et al., 2010; Polo et al., 2010; Zhao and
Xu, 2010; Gore et al., 2011; Lister et al., 2011). It is possible
that those defects can directly or indirectly contribute to the
immunogenicity of iPSC derivatives. In supporting of this
idea, we have identiﬁed a couple of genes overexpressed in
iPSC-teratomas, with two genes were conﬁrmed as direct
antigens contribute to the immunogenicity of iPSC deriva-
tives. This indicates that not all genes with abnormal
expression during differentiation will contribute to the
immune rejection responses after transplantation. On the





















Figure 1. Differential immunogenicity of iPSC derivatives. The genetic and epigenetic defects induced by reprogramming are
differentially presented during the iPSC differentiation leading to different consequences. The iPSC descendents without presentation
of the defects during differentiation are not immunogenic. Tissues with pronounced defects are immunogenic, but may have distinct
destiny.
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other hand, it is very hard to link the abnormal antigen
expression identiﬁed in teratomas to an exact cell type, due
to the heterogenic structure of teratomas. And the com-
plexity of developmental process makes it difﬁcult to predict
which tissue will inherit and present the defects induced by
reprogramming during iPSC development and differentia-
tion. So it is not surprising that both Abe and Boyd groups did
not detect abnormal gene expression in a speciﬁc cell types.
A possible solution to this question is to proﬁle the immu-
nogenicity of different tissues as much as possible. For those
immunogenic iPSC derived speciﬁc tissues, gene expres-
sion proﬁling can be employed to probe the minor antigens
contributed to the immunogenicity.
In general, compared to the allograft, the immunogenicity
of autologous iPSC derivatives is much weaker, supporting
not only by the high teratoma formation rate by B6 iPSCs
than allogeneic 129 ES cells in the B6 mice, but also the fact
that T cells are only locally but not ubiquitously inﬁltrated into
the teratomas formed by iPSC in B6 mice.
It is noteworthy however, if one certain cell linear differ-
entiated from iPSC expresses immunogenic minor antigens
ubiquitously, it still can elicit serious rejection responses,
leading to the complete rejection of that tissue (Fig. 1).
Which kind of tissues differentiated from iPSCs can be
immunogenic and whether they are destined is still an
important opening question. Furthermore, it is critical to
evaluate the immunogenicity of clinical valuable cells derived
from human iPSCs, which can signiﬁcantly promote the
translation of iPSC technology from bench to bedsides.
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